SVB Leerink Maintains Market Perform on Aligos Therapeutics, Lowers Price Target to $2
SVB Leerink analyst Roanna Ruiz maintains Aligos Therapeutics (NASDAQ:ALGS) with a Market Perform and lowers the price target from $3 to $2.
Aligos Therapeutics To Present Nonclinical And Clinical Data For Its Chronic Hepatitis B And NASH Portfolio At AASLD’s The Liver Meeting 2022 November 4-8
Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced seven upcoming
Aligos Co-Founders File Complaint Against Johnson & Johnson Alleging Fraud
Aligos Therapeutics Inc (NASDAQ:ALGS) has filed a response to the complaint of and counterclaims against Janssen Biopharma. In November 2014, Johnson…
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Aligos Therapeutics Earnings Preview
Aligos Therapeutics (NASDAQ:ALGS) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement.
Analysts estimate that Aligos Therapeutics will report an earnings per share (EPS) of $-0.67.
Aligos Therapeutics Has Received A Notice Of Allowance For Its U.S. Patent Application
https://patentcenter.uspto.gov/#!/applications/16887063/ifw/docs
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Preview: Aligos Therapeutics’s Earnings
Aligos Therapeutics (NASDAQ:ALGS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement.
Analysts estimate that Aligos Therapeutics will report an earnings per share (EPS) of $-0.73.
